CN104094121B - 用于诊断中风的nt-原anp和nt-原bnp - Google Patents

用于诊断中风的nt-原anp和nt-原bnp Download PDF

Info

Publication number
CN104094121B
CN104094121B CN201280068882.4A CN201280068882A CN104094121B CN 104094121 B CN104094121 B CN 104094121B CN 201280068882 A CN201280068882 A CN 201280068882A CN 104094121 B CN104094121 B CN 104094121B
Authority
CN
China
Prior art keywords
subject
sample
ischemic attack
transient ischemic
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280068882.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104094121A (zh
Inventor
G.赫斯
A.霍希
D.祖内克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201610812599.8A priority Critical patent/CN107064516B/zh
Publication of CN104094121A publication Critical patent/CN104094121A/zh
Application granted granted Critical
Publication of CN104094121B publication Critical patent/CN104094121B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201280068882.4A 2011-12-01 2012-11-29 用于诊断中风的nt-原anp和nt-原bnp Active CN104094121B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610812599.8A CN107064516B (zh) 2011-12-01 2012-11-29 用于诊断中风的nt-原anp和nt-原bnp

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11191579.9 2011-12-01
EP11191579 2011-12-01
PCT/EP2012/073897 WO2013079567A2 (en) 2011-12-01 2012-11-29 Nt-proanp and nt-probnp for the diagnosis of stroke

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610812599.8A Division CN107064516B (zh) 2011-12-01 2012-11-29 用于诊断中风的nt-原anp和nt-原bnp

Publications (2)

Publication Number Publication Date
CN104094121A CN104094121A (zh) 2014-10-08
CN104094121B true CN104094121B (zh) 2016-10-26

Family

ID=47278813

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280068882.4A Active CN104094121B (zh) 2011-12-01 2012-11-29 用于诊断中风的nt-原anp和nt-原bnp
CN201610812599.8A Active CN107064516B (zh) 2011-12-01 2012-11-29 用于诊断中风的nt-原anp和nt-原bnp

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610812599.8A Active CN107064516B (zh) 2011-12-01 2012-11-29 用于诊断中风的nt-原anp和nt-原bnp

Country Status (7)

Country Link
US (2) US10732188B2 (https=)
EP (2) EP3290924B1 (https=)
JP (2) JP6059735B2 (https=)
CN (2) CN104094121B (https=)
CA (2) CA2856461C (https=)
ES (2) ES2656082T3 (https=)
WO (1) WO2013079567A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016056664A1 (ja) * 2014-10-10 2016-04-14 松森　昭 心不全患者の検出方法、心疾患の識別方法、心不全の検査試薬、心不全の検査キット、心不全を検出するための装置及び心不全を検出するためのプログラム
KR20210038893A (ko) * 2018-07-31 2021-04-08 에프. 호프만-라 로슈 아게 심방 세동의 평가에서 순환하는 dkk3(딕오프 관련 단백질 3)
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
JP7698310B2 (ja) * 2019-05-16 2025-06-25 フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ 再灌流療法のために患者を選択する方法
JP2021173559A (ja) 2020-04-21 2021-11-01 株式会社デンソー 物理量計測装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1938431A (zh) * 2004-03-29 2007-03-28 塞诺菲-安万特德国有限公司 发生血栓性疾病的素质的诊断方法及其用途
WO2007042165A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
ATE458199T1 (de) 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
ATE462001T1 (de) * 2002-12-24 2010-04-15 Nitto Boseki Co Ltd Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
US20050181386A1 (en) * 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
US20060166303A1 (en) * 2005-01-24 2006-07-27 Eberhard Spanuth Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
EP1849009B1 (en) 2005-01-24 2008-10-29 F. Hoffmann-La Roche AG The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs.
WO2006087373A1 (en) * 2005-02-17 2006-08-24 F. Hoffmann-La Roche Ag Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
DE602006014798D1 (de) * 2006-03-24 2010-07-22 Roche Diagnostics Gmbh Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten
EP1882945A1 (en) 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath
EP1901072B1 (en) * 2006-09-15 2009-11-25 F. Hoffman-la Roche AG Biochemical markers for acute pulmonary embolism
EP2210111A1 (en) 2007-10-10 2010-07-28 Roche Diagnostics GmbH Natriuretic peptide/troponin ratio for the assessment of preexisting myocardial dysfunction in patients with acute coronary syndrome
CN102257386B (zh) * 2008-10-24 2014-12-31 B.R.A.H.M.S有限公司 通过测定标志肽的水平在已患过中风或短暂性缺血性发作的患者中进行预后和风险评估
US8486652B2 (en) * 2009-01-30 2013-07-16 Bio-Rad Innovations Method for the in vitro diagnosis of stroke
EP2466311A1 (en) 2010-12-17 2012-06-20 Roche Diagnostics GmbH sFlt1 in patients with ischemic stroke

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1938431A (zh) * 2004-03-29 2007-03-28 塞诺菲-安万特德国有限公司 发生血栓性疾病的素质的诊断方法及其用途
WO2007042165A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunohistochemical modifications of vasoactive neuropeptides and excitatory amino acids in the nervous tissue of the mongolian gerbil after transient cerebral ischemia;ROSARIO GIUFFRIDA et al.;《International journal of developmental neuroscience》;19990401;第17卷(第2期);摘要，图3 *

Also Published As

Publication number Publication date
CA3081979C (en) 2023-07-11
EP3290924B1 (en) 2021-10-13
ES2656082T3 (es) 2018-02-23
WO2013079567A2 (en) 2013-06-06
WO2013079567A3 (en) 2013-08-29
JP2015504519A (ja) 2015-02-12
JP6059735B2 (ja) 2017-01-11
JP2017075959A (ja) 2017-04-20
JP6441885B2 (ja) 2018-12-19
EP3290924A1 (en) 2018-03-07
EP2786154A2 (en) 2014-10-08
CN104094121A (zh) 2014-10-08
US10732188B2 (en) 2020-08-04
CN107064516B (zh) 2019-08-02
CA3081979A1 (en) 2013-06-06
US20140274793A1 (en) 2014-09-18
CN107064516A (zh) 2017-08-18
HK1201327A1 (en) 2015-08-28
US20200333360A1 (en) 2020-10-22
ES2899923T3 (es) 2022-03-15
CA2856461A1 (en) 2013-06-06
CA2856461C (en) 2020-08-18
EP2786154B1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
CN104094121B (zh) 用于诊断中风的nt-原anp和nt-原bnp
CN104769436B (zh) 阵发性心房纤颤的基于TnT的诊断
US11047865B2 (en) Troponin and BNP based diagnosis of risk patients and cause of stroke
JP2020034564A (ja) 心不全リスクの予測改善のためのバイオマーカー
HK1241021B (zh) 用於诊断中风的nt-原anp和nt-原bnp
HK1241021A1 (en) Nt-proanp and nt-probnp for the diagnosis of stroke
HK1201327B (en) Nt-proanp and nt-probnp for the diagnosis of stroke
HK1212434B (en) Tnt based diagnosis of paroxysmal atrial fibrillation
HK1224745A1 (en) Troponin and bnp based diagnosis of risk patients and cause of stroke
HK1196158B (en) Troponin and bnp based diagnosis of risk patients and cause of stroke

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201327

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201327

Country of ref document: HK